REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
12 hedge funds and large institutions have $2.05M invested in REVIVA PHARMA HLDGS INC in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.01% less ownership
Funds ownership: 0.63% → 0.62% (-0.01%)
20% less funds holding
Funds holding: 15 → 12 (-3)
56% less capital invested
Capital invested by funds: $4.68M → $2.05M (-$2.63M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.3K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$10.5K |
| 3 |
Renaissance Technologies
New York
|
+$9.63K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$56K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$54.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$2.24K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.23K |
| 5 |
JP Morgan Chase
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
1
Tang Capital Management
San Diego,
California
| $1.32M | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $511K | -$1.23K | -35 | -0.2% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $88K | +$4.55K | +130 | +3% |
|
|
ECM
4
EMC Capital Management
Houston,
Texas
| $62K | – | – | – |
|
|
RJA
5
Raymond James & Associates
St Petersburg,
Florida
| $22K | +$10.5K | +300 | +43% |
|
|
6
Renaissance Technologies
New York
| $20K | +$9.63K | +275 | +43% |
|
7
Northern Trust
Chicago,
Illinois
| $12K | – | – | – |
|
8
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $10K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $8K | +$11.3K | +323 | +1,468% |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$54.8K | -1,565 | Closed |
|
|
11
BlackRock
New York
| – | -$56K | -1,142 | Closed |
|
|
12
Simplex Trading
Chicago,
Illinois
| – | -$2.24K | -64 | -96% |
|
|
13
JP Morgan Chase
New York
| – | -$1K | -17 | Closed |
|
14
Wells Fargo
San Francisco,
California
| – | -$35 | -1 | -20% |
|
RVPH Hedge Fund Activity: Q2 2022 in Review
12 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2022, worth a combined $2.05M — down 56% from $4.68M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of RVPH and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $11.3K. The largest seller was BlackRock, exiting entirely with an estimated $56K sold.
- 12 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2022, down from 15 in Q1 2022.
- Funds reported $2.05M of REVIVA PHARMA HLDGS INC stock for Q2 2022, down 56% quarter-over-quarter.
- 0 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2022 and 3 closed out, a net change of -3 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2022 was Tower Research Capital (TRC), an estimated $11.3K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2022 was BlackRock, an estimated $56K sold.
Based on aggregated 13F filings for Q2 2022.